Publications

• New targets to treat obesity and the metabolic syndrome.Martin KA, Mani MV, Mani A. Eur J Pharmacol. 2015 Sep 15; 2015 May 19. PMID: 26001373.
• Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor.Xiang Y, Cheng J, Wang D, Hu X, Xie Y, Stitham J, Atteya G, Du J, Tang WH, Lee SH, Leslie K, Spollett G, Liu Z, Herzog E, Herzog RI, Lu J, Martin KA, Hwa J. Blood. 2015 May 28; 2015 Mar 26. PMID: 25814526.
• Phosphorylation of GATA-6 is required for vascular smooth muscle cell differentiation after mTORC1 inhibition.Xie Y, Jin Y, Merenick BL, Ding M, Fetalvero KM, Wagner RJ, Mai A, Gleim S, Tucker DF, Birnbaum MJ, Ballif BA, Luciano AK, Sessa WC, Rzucidlo EM, Powell RJ, Hou L, Zhao H, Hwa J, Yu J, Martin KA. Sci Signal. 2015 May 12; 2015 May 12. PMID: 25969542.
• Epigenetic regulation of smooth muscle cell plasticity.Liu R, Leslie KL, Martin KA. Biochim Biophys Acta. 2015 Apr; 2014 Jun 15. PMID: 24937434.
• The magic touch: endothelial cells muscle-up adipose.Martin KA, Hirschi KK. Circ Res. 2014 Oct 10. PMID: 25301822.
• Response to letter regarding article, "ten-eleven translocation-2 (TET2) is a master regulator of smooth muscle cell plasticity".Liu R, Jin Y, Tang W, Qin L, Zhang X, Tellides G, Hwa J, Yu J, Martin KA. Circulation. 2014 Aug 19. PMID: 25135133.
• Aldose reductase-mediated phosphorylation of p53 leads to mitochondrial dysfunction and damage in diabetic platelets.Tang WH, Stitham J, Jin Y, Liu R, Lee SH, Du J, Atteya G, Gleim S, Spollett G, Martin K, Hwa J. Circulation. 2014 Apr 15; 2014 Jan 28. PMID: 24474649.
• Resveratrol induces vascular smooth muscle cell differentiation through stimulation of SirT1 and AMPK.Thompson AM, Martin KA, Rzucidlo EM. PLoS One. 2014; 2014 Jan 8. PMID: 24416418.
• Pharmacogenetics of obesity drug therapy.Guzman AK, Ding M, Xie Y, Martin KA. Curr Mol Med. 2014. PMID: 25109792.
• Ten-eleven translocation-2 (TET2) is a master regulator of smooth muscle cell plasticity.Liu R, Jin Y, Tang WH, Qin L, Zhang X, Tellides G, Hwa J, Yu J, Martin KA. Circulation. 2013 Oct 29; 2013 Sep 27. PMID: 24077167.
• Human thromboxane A2 receptor genetic variants: in silico, in vitro and "in platelet" analysis.Gleim S, Stitham J, Tang WH, Li H, Douville K, Chelikani P, Rade JJ, Martin KA, Hwa J. PLoS One. 2013; 2013 Jun 28. PMID: 23840660.
• NO triggers RGS4 degradation to coordinate angiogenesis and cardiomyocyte growth.Jaba IM, Zhuang ZW, Li N, Jiang Y, Martin KA, Sinusas AJ, Papademetris X, Simons M, Sessa WC, Young LH, Tirziu D. J Clin Invest. 2013 Apr. PMID: 23454748.
• Modeling supravalvular aortic stenosis syndrome with human induced pluripotent stem cells.Ge X, Ren Y, Bartulos O, Lee MY, Yue Z, Kim KY, Li W, Amos PJ, Bozkulak EC, Iyer A, Zheng W, Zhao H, Martin KA, Kotton DN, Tellides G, Park IH, Yue L, Qyang Y. Circulation. 2012 Oct 2; 2012 Aug 22. PMID: 22914687.
• An eicosanoid-centric view of atherothrombotic risk factors.Gleim S, Stitham J, Tang WH, Martin KA, Hwa J. Cell Mol Life Sci. 2012 Oct; 2012 Apr 11. PMID: 22491820.
• Aldose reductase, oxidative stress, and diabetic mellitus.Tang WH, Martin KA, Hwa J. Front Pharmacol. 2012; 2012 May 9. PMID: 22582044.
• Vascular smooth muscle cell-derived adiponectin: a paracrine regulator of contractile phenotype.Ding M, Carrão AC, Wagner RJ, Xie Y, Jin Y, Rzucidlo EM, Yu J, Li W, Tellides G, Hwa J, Aprahamian TR, Martin KA. J Mol Cell Cardiol. 2012 Feb; 2011 Sep 17. PMID: 21952104.
• Adiponectin in the heart and vascular system.Ding M, Rzucidlo EM, Davey JC, Xie Y, Liu R, Jin Y, Stavola L, Martin KA. Vitam Horm. 2012. PMID: 23017720.
• Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane.Tang WH, Stitham J, Gleim S, Di Febbo C, Porreca E, Fava C, Tacconelli S, Capone M, Evangelista V, Levantesi G, Wen L, Martin K, Minuz P, Rade J, Patrignani P, Hwa J. J Clin Invest. 2011 Nov; 2011 Oct 17. PMID: 22005299.
• Adiponectin induces vascular smooth muscle cell differentiation via repression of mammalian target of rapamycin complex 1 and FoxO4.Ding M, Xie Y, Wagner RJ, Jin Y, Carrao AC, Liu LS, Guzman AK, Powell RJ, Hwa J, Rzucidlo EM, Martin KA. Arterioscler Thromb Vasc Biol. 2011 Jun; 2011 Mar 31. PMID: 21454807.
• Prostacyclin: an inflammatory paradox.Stitham J, Midgett C, Martin KA, Hwa J. Front Pharmacol. 2011; 2011 May 13. PMID: 21687516.
• Comprehensive biochemical analysis of rare prostacyclin receptor variants: study of association of signaling with coronary artery obstruction.Stitham J, Arehart E, Elderon L, Gleim SR, Douville K, Kasza Z, Fetalvero K, MacKenzie T, Robb J, Martin KA, Hwa J. J Biol Chem. 2011 Mar 4; 2010 Dec 28. PMID: 21189259.
• Lovastatin induces VSMC differentiation through inhibition of Rheb and mTOR.Wagner RJ, Martin KA, Powell RJ, Rzucidlo EM. Am J Physiol Cell Physiol. 2010 Jul; 2010 Apr 7. PMID: 20375271.
• Activation of Hedgehog signaling by the environmental toxicant arsenic may contribute to the etiology of arsenic-induced tumors.Fei DL, Li H, Kozul CD, Black KE, Singh S, Gosse JA, DiRenzo J, Martin KA, Wang B, Hamilton JW, Karagas MR, Robbins DJ. Cancer Res. 2010 Mar 1; 2010 Feb 23. PMID: 20179202.
• Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation.Kasza Z, Fetalvero KM, Ding M, Wagner RJ, Acs K, Guzman AK, Douville KL, Powell RJ, Hwa J, Martin KA. J Mol Cell Cardiol. 2009 May; 2009 Jan 23. PMID: 19302827.
• The human prostacyclin receptor from structure function to disease.Martin KA, Gleim S, Elderon L, Fetalvero K, Hwa J. Prog Mol Biol Transl Sci. 2009; 2009 Oct 7. PMID: 20374736.
• Prostacyclin primes pregnant human myometrium for an enhanced contractile response in parturition.Fetalvero KM, Zhang P, Shyu M, Young BT, Hwa J, Young RC, Martin KA. J Clin Invest. 2008 Dec; 2008 Nov 20. PMID: 19033666.
• Shp shape: FAKs about hypertrophy.Martin KA, Hwa J. Circ Res. 2008 Oct 10. PMID: 18845815.
• Syndecan-4 regulates subcellular localization of mTOR Complex2 and Akt activation in a PKCalpha-dependent manner in endothelial cells.Partovian C, Ju R, Zhuang ZW, Martin KA, Simons M. Mol Cell. 2008 Oct 10. PMID: 18851840.
• Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition.Arehart E, Stitham J, Asselbergs FW, Douville K, MacKenzie T, Fetalvero KM, Gleim S, Kasza Z, Rao Y, Martel L, Segel S, Robb J, Kaplan A, Simons M, Powell RJ, Moore JH, Rimm EB, Martin KA, Hwa J. Circ Res. 2008 Apr 25; 2008 Mar 6. PMID: 18323528.